By Most people interact with the healthcare system reactively – when something hurts, when a symptom appears, when a crisis develops. Preventive screening turns that model around. It looks for problems before symptoms develop, at a stage when intervention is most effective and damage is most reversible.
The evidence for screening is not uniform across all tests and all populations. Some screenings have strong evidence for saving lives in specific age and risk groups. Others are widely performed but offer less clear benefit, and some popular tests are not recommended by major guidelines at all. Understanding which screenings matter, for whom, and at what age is more valuable than a blanket “get everything checked every year” approach.
This article covers the evidence-based preventive screenings recommended for US adults by major bodies including the US Preventive Services Task Force (USPSTF), the American Cancer Society (ACS), the American Heart Association (AHA), the American Diabetes Association (ADA), and the CDC – with context for who each applies to and why.
The Logic of Screening: When It Helps and When It Doesn’t
A screening test is only valuable if it meets certain criteria: the condition it detects must be common enough to justify population-level testing, must have a pre-symptomatic detectable phase, must have an effective treatment that’s better when started early, and the test itself must be accurate enough (sensitive and specific) that its benefits outweigh its harms (false positives, overdiagnosis, unnecessary procedures).
Not every test meets these criteria for every population. This is why guidelines specify age ranges, risk groups, and testing intervals – and why some tests your doctor orders are diagnostic (because you have symptoms) rather than screening (in the absence of symptoms). Understanding that distinction matters.
The USPSTF – the independent expert body that evaluates preventive services in the US – grades recommendations from A (strongly recommend) to D (recommend against). Grade A and B recommendations are those with high-quality evidence of net benefit.
Blood Pressure Screening
Who: All adults How often: At least every 2 years if normal (below 120/80 mmHg); annually if elevated (120-129 systolic) or stage 1 hypertension (130-139/80-89 mmHg); more frequently with known hypertension or significant risk factors USPSTF grade: A (strongly recommend)
Hypertension affects approximately 47% of US adults and is the leading modifiable risk factor for cardiovascular disease, stroke, and kidney disease. It produces no symptoms until significant organ damage has occurred, making screening essential.
Blood pressure measurement is fast, inexpensive, and entirely non-invasive. The single most impactful thing about blood pressure screening is ensuring it’s done correctly: seated, rested for 5 minutes, arm at heart level, using a properly sized cuff, taking the average of two readings. Single elevated readings should be confirmed on repeat visits before diagnosis.
The AHA recommends home blood pressure monitoring as a standard part of hypertension management and diagnosis. Validated upper-arm home cuffs (around $25-50) provide more representative readings than isolated clinic measurements.
Cholesterol and Lipid Panel
Who: Men starting at 35; women starting at 45; earlier (starting at 20) for those with elevated cardiovascular risk (diabetes, smoking, family history of early heart disease, obesity) How often: Every 5 years if normal and low risk; more frequently with elevated levels or cardiovascular risk factors USPSTF grade: B for high-risk younger adults; recommendation for universal adult screening varies by guideline source
A lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides – the core components used to assess cardiovascular risk. LDL is the primary target of cardiovascular risk reduction.
Fasting vs non-fasting: non-fasting lipid panels are acceptable for initial screening in most adults – fasting primarily affects triglycerides. If triglycerides are elevated on a non-fasting test, a fasting repeat provides more accurate results.
What matters beyond the numbers: modern cardiovascular risk assessment uses lipid values alongside age, sex, blood pressure, smoking status, and diabetes history to calculate 10-year cardiovascular risk (using tools like the ACC/AHA Pooled Cohort Equations). This risk-based approach determines who benefits from statin therapy – not cholesterol levels alone.
Blood Sugar: Diabetes and Prediabetes Screening
Who: Adults aged 35-70 who are overweight or have obesity; earlier for those with additional risk factors (family history, prior gestational diabetes, PCOS, certain ethnic backgrounds with higher risk) How often: Every 3 years if normal; annually if prediabetes is present USPSTF grade: B
Type 2 diabetes affects approximately 38 million Americans and prediabetes affects another 98 million – most of whom are unaware. Both conditions develop silently over years before symptoms appear.
Screening tests:
- Fasting plasma glucose (FPG): After 8 hours fasting; normal below 100 mg/dL, prediabetes 100-125, diabetes 126+
- HbA1c: No fasting required; measures average blood glucose over 3 months; normal below 5.7%, prediabetes 5.7-6.4%, diabetes 6.5%+
- Oral glucose tolerance test (OGTT): Most sensitive but cumbersome – used in specific situations including pregnancy screening
The ADA recommends considering screening at any age for those with BMI ≥25 (≥23 for Asian Americans) plus one or more risk factors, including hypertension, dyslipidemia, family history, physical inactivity, PCOS, or prior gestational diabetes.
Early detection of prediabetes is particularly valuable: the Diabetes Prevention Program demonstrated that lifestyle intervention (150 minutes of weekly activity plus modest weight loss) reduces progression from prediabetes to type 2 diabetes by 58% – more effectively than metformin.
Colorectal Cancer Screening
Who: All adults aged 45-75; individualized decision from 76-85; not recommended after 85 How often: Depends on method chosen (see below) USPSTF grade: A for ages 45-75; B for 76-85
Colorectal cancer is the third most common cancer and second leading cause of cancer death in the US – and one of the most preventable because it almost always develops from precancerous polyps that can be removed before becoming malignant. Screening reduces colorectal cancer mortality by up to 60%.
In 2021 the USPSTF lowered the screening start age from 50 to 45, reflecting increasing rates of colorectal cancer in younger adults.
Screening options:
| Test | Frequency | What It Detects |
|---|---|---|
| Colonoscopy | Every 10 years | Polyps and cancer; allows removal during procedure |
| Stool-based FIT (Fecal Immunochemical Test) | Annually | Blood in stool – highly convenient, no prep |
| Stool DNA test (Cologuard) | Every 1-3 years | DNA and blood markers; more sensitive than FIT but more false positives |
| CT colonography (virtual colonoscopy) | Every 5 years | Structural view of colon; requires bowel prep, no polyp removal |
| Flexible sigmoidoscopy | Every 5 years | Examines lower colon only |
Colonoscopy is the gold standard because it’s diagnostic and therapeutic simultaneously – polyps found can be removed during the same procedure. Stool-based tests are excellent options for those who decline colonoscopy, are equally appropriate as a first-line choice, and have strong evidence for mortality reduction. A positive stool-based test requires follow-up colonoscopy.
Cervical Cancer Screening (Pap Smear and HPV Test)
Who: Women aged 21-65 How often: Pap test alone every 3 years (ages 21-65); or Pap + HPV co-test every 5 years (ages 30-65) USPSTF grade: A
Cervical cancer is almost entirely caused by persistent HPV infection. Routine screening has reduced cervical cancer rates dramatically over the past 50 years. The addition of HPV testing to Pap smear allows longer intervals between tests in women with normal results.
HPV vaccination (Gardasil 9) dramatically reduces the risk of cervical cancer from the most oncogenic HPV strains. The CDC recommends vaccination through age 26 for everyone, and shared clinical decision-making for vaccination at ages 27-45. Vaccinated women should still follow screening guidelines because existing infection or less common HPV types are not covered by the vaccine.
Women who have had total hysterectomy (including cervix removal) for non-cancer reasons and have no prior history of cervical cancer or high-grade precancerous lesions do not need continuing cervical screening.
Breast Cancer Screening
Who: Women; recommendations vary significantly by guideline body (see below) USPSTF 2024 update: Annual mammography starting at age 40 for average-risk women (updated from the previous recommendation that left 40-49 as individual decision) ACS recommendation: Annual mammography starting at 45 for average-risk women; option to start at 40 For high-risk women (BRCA1/2 carriers, strong family history, prior chest radiation): screening typically starts earlier and may include annual breast MRI alongside mammography
The mammography recommendation was updated by the USPSTF in 2024 specifically in response to evidence that Black women develop breast cancer at younger ages on average and face higher breast cancer mortality, making earlier universal screening more beneficial than previously assessed.
Dense breast tissue – present in approximately 40% of women – reduces mammogram sensitivity. Women should be informed of their breast density (now required by federal law in the US); those with dense breasts and average risk should discuss additional screening options with their provider.
Lung Cancer Screening
Who: Adults aged 50-80 who have a 20 pack-year smoking history AND currently smoke or quit within the past 15 years How often: Annually with low-dose CT (LDCT) scan USPSTF grade: B
Lung cancer is the leading cause of cancer death in the US. Annual LDCT screening in high-risk smokers reduces lung cancer mortality by approximately 20% (National Lung Screening Trial) to 24% (NELSON trial). The USPSTF expanded eligibility in 2021 from the previous 55-80 age range and 30 pack-year history, significantly increasing the eligible population.
A “pack-year” is one pack per day for one year – so 20 pack-years could be 1 pack/day for 20 years, 2 packs/day for 10 years, or any equivalent combination.
Screening is paired with smoking cessation counseling – quitting smoking remains the most effective single intervention for reducing lung cancer risk.
Abdominal Aortic Aneurysm Screening
Who: Men aged 65-75 who have ever smoked (at least 100 cigarettes in their lifetime) How once: One-time abdominal ultrasound USPSTF grade: B
An abdominal aortic aneurysm (AAA) – a dangerous bulging of the aorta – ruptures with very high mortality. A single abdominal ultrasound in the target population detects the majority of clinically significant aneurysms, allowing monitoring and elective repair before rupture. The evidence for benefit is specifically in men who have smoked; evidence for women is insufficient to recommend routine screening.
Depression Screening
Who: All adults; pregnant and postpartum women specifically highlighted How often: At regular health visits; frequency varies by guideline USPSTF grade: B
Depression affects approximately 1 in 6 Americans at some point in their lifetime and is substantially underdiagnosed in primary care. Simple validated screening tools (PHQ-2 and PHQ-9) take under 2 minutes to complete and reliably identify depression that might otherwise be missed.
Screening is most valuable when connected to adequate follow-up resources – diagnosis without access to treatment is of limited value.
Additional Screenings by Risk Group
Osteoporosis (bone density DEXA scan):
- Women aged 65+: all recommended (USPSTF Grade B)
- Women under 65 with risk factors (early menopause, long-term corticosteroid use, low body weight, family history): screening recommended at the age risk equals that of a 65-year-old white woman without risk factors
- Men: insufficient USPSTF evidence; many guidelines recommend screening at 70+
STI Screening:
- HIV: USPSTF recommends HIV screening for all adults aged 15-65 (Grade A); annually for those at increased risk
- Syphilis, gonorrhea, chlamydia: annual screening for sexually active women under 25 and older women at increased risk; screening for all sexually active people at increased risk regardless of gender
- Hepatitis C: one-time screening for all adults 18-79 (USPSTF Grade B); critical because effective curative treatments now exist
Hepatitis B: Screening recommended for adults at increased risk; vaccination for those not immune
Skin cancer: The USPSTF currently finds insufficient evidence to recommend routine visual skin cancer screening in the general population; however, primary prevention (sunscreen use, sun protection) is strongly supported
Immunizations: Prevention That Works
Screenings detect early disease. Vaccines prevent it. The adult immunization schedule recommended by the CDC Advisory Committee on Immunization Practices (ACIP) for adults includes:
- Influenza (flu): Annually for all adults
- Tdap/Td: One Tdap dose if not previously received; Td booster every 10 years
- COVID-19: Per current CDC guidance (updated annually)
- Shingles (Zoster/Shingrix): Two doses for adults 50+; highly effective against shingles and post-herpetic neuralgia
- Pneumococcal vaccines: For adults 65+ and younger adults with certain conditions
- RSV vaccine: For adults 60+; recommended since 2023 approval
- HPV vaccine: Through age 26 for all; shared decision-making 27-45
How Often Should You Have a General Health Visit?
The annual physical has evolved considerably. Most major guidelines now recommend:
- Adults 18-39 with no chronic conditions: general health visit every 2-3 years
- Adults 40-49: every 1-2 years
- Adults 50+: annually
- Anyone with chronic conditions (hypertension, diabetes, heart disease, etc.): as frequently as their condition warrants
The value of the visit comes from the combination of relationship with a provider, blood pressure measurement, updating screening status, discussing risk factors, and addressing emerging concerns – not from ordering a battery of tests regardless of indication.
Frequently Asked Questions
Should I get a full body scan or comprehensive blood panel “just to check everything”? Not as routine preventive care. Full-body CT scans expose you to significant radiation and produce numerous incidental findings – the majority of which are benign but require follow-up testing that carries its own risks and anxiety. Comprehensive laboratory panels ordered without specific indication frequently generate abnormal results that are statistical outliers rather than true disease, leading to unnecessary procedures. Evidence-based screening means targeted tests with demonstrated benefit – not more tests for the sake of thoroughness.
My family has a history of heart disease. Should I screen earlier or differently? Yes – family history of premature cardiovascular disease (first-degree relative with heart attack or coronary artery disease before age 55 in men, 65 in women) is an independent risk factor that shifts screening and treatment thresholds. Discuss your family history specifically with your doctor – it may warrant earlier lipid screening, lower LDL targets, and earlier consideration of preventive medication.
I’m 35 with no symptoms and feel fine. Do I really need any screening? Blood pressure should be checked at least every 2 years from young adulthood – hypertension often develops in the 30s and produces no symptoms. If you have risk factors for diabetes (family history, overweight, certain ethnic backgrounds), blood glucose should be checked. Cervical cancer screening applies from age 21 for women. STI screening applies based on sexual activity and risk factors at any age. Feeling well is not evidence that blood pressure, glucose, and lipids are normal – these conditions are characteristically silent.
What’s the difference between a screening test and a diagnostic test? A screening test is performed in someone without symptoms to detect early or pre-symptomatic disease. A diagnostic test is performed because symptoms or other findings suggest a specific condition. This distinction matters because the same test may be appropriate diagnostically but not as a screening tool – and because insurance coverage often depends on which category applies.
Do I need to fast before my blood tests? Fasting requirements depend on what’s being tested. Fasting glucose and triglycerides require 8-12 hours of fasting. HbA1c, lipid panel (for most purposes), kidney function, thyroid function, and CBC do not require fasting. Ask specifically when scheduling – showing up fasted when not required is unnecessary, and showing up unfasted when required invalidates results.
Disclaimer
This article is for educational purposes only and does not constitute medical advice. Screening recommendations vary based on individual risk factors, family history, and clinical context. Discuss which screenings are appropriate for you with your healthcare provider. Screening guidelines are updated periodically – the information here reflects guidance current at time of writing but may change.
References
- US Preventive Services Task Force. Published recommendations. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics
- American Cancer Society. Cancer screening guidelines. https://www.cancer.org/cancer/screening.html
- American Heart Association. Heart-health screenings. https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease/heart-health-screenings
- American Diabetes Association. Standards of medical care in diabetes – 2024. Diabetes Care. 2024;47(Suppl 1). https://doi.org/10.2337/dc24-S001
- Centers for Disease Control and Prevention (CDC). Adult immunization schedule. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html
- National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine. 2011;365(5):395-409. https://doi.org/10.1056/NEJMoa1102873
- Leddin D, Lieberman DA, Tse F, et al. Clinical practice guideline on screening for colorectal neoplasia in individuals with a family history. Gastroenterology. 2018;154(7):1929-1946. https://doi.org/10.1053/j.gastro.2018.03.017
- Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (DPP). New England Journal of Medicine. 2002;346(6):393-403. https://doi.org/10.1056/NEJMoa012512
- USPSTF. Breast cancer: screening. 2024 recommendation statement. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
- Centers for Disease Control and Prevention (CDC). Preventive health care. https://www.cdc.gov/healthequity/features/preventive-care/index.html
